Drugs / OLODANRIGAN
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03297294 | Mar 2018 → Mar 2019 | diabetic polyneuropathy | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT03094195 | Jun 2017 → Mar 2019 | postherpetic neuralgia | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT02426411 | Jun 2015 → Oct 2016 | postherpetic neuralgia | Spinifex Pharmaceuticals Pty Ltd | Withdrawn | No outcome recorded |
| Phase 2 | NCT02435199 | Jun 2015 → Oct 2016 | diabetic neuropathy | Spinifex Pharmaceuticals Pty Ltd | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLODANRIGAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL34124 ↗ |
| Known as | EMA401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02426411 ↗ |
| Known as | PD-126055 | ChEMBL registry synonym — accepted as the source's own label CHEMBL34124 ↗ |
| Action | Inhibit | “EMA401 (a highly selective angiotensin II type 2 receptor antagonist)” PMID 33675631 ↗ Oct 20211“Angiotensin II type 2 (AT-2) receptor antagonist” CHEMBL34124 ↗ |
| Modality | Small molecule | — CHEMBL34124 ↗ |
| Route | Oral | “Ema401 25 mg was administered orally twice a day” NCT03094195 ↗ |
| Target | AGTR2 | “Angiotensin II type 2 (AT-2) receptor antagonist” CHEMBL34124 ↗ |